TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01833845
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weight-based doses (1000 mg/day administered BID \[twice daily\] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects \> 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
Study: NCT01833845
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
Study: NCT01236534
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mcg twice daily for 21 days.
Study: NCT00491725
Drug: repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00491725
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03734159
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study: NCT03734159
Drug: sodium chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
Study: NCT00580242
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study: NCT00580242
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study: NCT00580242
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
Study: NCT01672450
Drug: Intratumoral Ipilimumab and Interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
Study: NCT00580242
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
Study: NCT01079663
Drug: Chlorhexidine 2.5 mg
Normalized name: chlorhexidine 2.5 MG
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01844687
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
Study: NCT02334163
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg nitazoxanide tablets twice daily
Study: NCT02334163
Drug: Oral lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral lactulose (65%)
Study: NCT02334163
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg metronidazole tablets every 8 hours
Study: NCT02334163
Drug: Rifaximine
Normalized name: Rifaximine
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two 200 mg rifaximine tablets every 8 hours
Study: NCT02144766
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caudal block with 1 ml/kg of ropivacaine 0.2%
Study: NCT02144766
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caudal block with 1 ml/kg of saline
Study: NCT01607411
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoride Toothpaste
Study: NCT01283204
Drug: SP
Normalized name: Asp
DrugBank: Aspartic acid (DB00128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \<Every 3 weeks\>~1. Day 1\~14 : TS-1 80mg/m2/day (PO),~2. Day 1 : CDDP 60mg/m2/day IVF 2hours,~3. Day 15\~21 : Rest.
Study: NCT03477162
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be given to patients prior to surgery.
Study: NCT01556191
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg per day (oral)
Study: NCT01556191
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
Study: NCT01556191
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg per day (oral)
Study: NCT01856868
Drug: (-)-epicatechin
Normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
Study: NCT00371683
Drug: Enoxaparin + Placebo
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
Study: NCT00371683
Drug: Apixaban + Placebo
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
Study: NCT04717245
Drug: Promestriene Vaginal
Normalized name: promestriene Vaginal Cream
DrugBank: Promestriene (DB12487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients used promestriene vaginal cream for 3 months. The use was recommended to be diary fot the first 2 weeks, and then, repeat every 3 days.
Study: NCT01486940
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
Study: NCT01486940
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
Study: NCT00092196
Drug: MK0869, aprepitant / Duration of Treatment: 3 days
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01507181
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose IV ketamine, .5mg/kg infused over 40 minutes
Study: NCT01507181
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose IV midazolam, .45mg/kg infused over 40 minutes
Study: NCT02546648
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02546648
Drug: Tranexamic Acid Placebo
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02785393
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The administration of a sugar pill
Study: NCT02785393
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The administration of the Doxazosin medication
Study: NCT01725685
Drug: FF 400 mcg
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
Study: NCT01725685
Drug: UMEC 500 mcg
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
Study: NCT01034163
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02355678
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV 0.5 mg/kg
Study: NCT02355678
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If Visual Analogue Scale was greater than 5
Study: NCT02355678
Drug: Propacetamol hydrochloride
Normalized name: Propacetamol hydrochloride
DrugBank: Propacetamol (DB09288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If Visual Analogue Scale was between 4 and 5
Study: NCT00526838
Drug: XL228
Normalized name: XL228
DrugBank: XL228 (DB05184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour IV infusion
Study: NCT02581631
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02148640
Drug: Innovator infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02148640
Drug: Biosimilar infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00702780
Drug: escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
Study: NCT03922880
Drug: ADI PEG20
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
Study: NCT03922880
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
Study: NCT03922880
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
Study: NCT03788694
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 doses of intranasal ketamine; 40 mg per dose.
Study: NCT00171613
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01128452
Drug: EVT 101
Normalized name: EVT-101
DrugBank: EVT-101 (DB05956)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC Capsule, 15 mg, once daily for 28 days
Study: NCT00584987
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 puffs of each nasal spray in each nostril in the pm
Study: NCT03107429
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide tablets were placed in capsules to make them look similar to placebo.
Study: NCT03735290
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
Study: NCT00122434
Drug: tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02960412
Drug: furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg lasix given intraoperatively
Study: NCT00005868
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005868
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02932436
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg per os daily for 12 weeks
Study: NCT02507570
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: used concomitantly
Study: NCT00584987
Drug: Placebo Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 puffs of each nasal spray in each nostril in the pm
Study: NCT03150082
Drug: Ciprofloxacin reference tablet
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side.
Study: NCT02487446
Drug: Umeclidinium/vilanterol
Normalized name: UMECLIDINIUM/VILANTEROL
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study: NCT02487446
Drug: Placebo (umeclidinium/vilanterol)
Normalized name: umeclidinium / vilanterol
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
Study: NCT02141451
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
Study: NCT02141451
Drug: INCB7839
Normalized name: INCB7839
DrugBank: INCB7839 (DB05033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
Study: NCT04463966
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gm (100 mg/ml) slowly intravenous infusion during delivery ( administered over 10 minutes at 1 ml/minute) .
Study: NCT03496389
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 300mg daily
Study: NCT02168829
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03496389
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol 50mg QID
Study: NCT03496389
Drug: Panadol
Normalized name: Panadol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panadol 500mg QID
Study: NCT01405560
Drug: Vaniprevir
Normalized name: Vaniprevir
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
Study: NCT01405560
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
Study: NCT03459443
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danicopan was to be administered as an oral tablet.
Study: NCT00584987
Drug: Oxymetazoline
Normalized name: Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puffs of each nasal spray in each nostril in the pm
Study: NCT00584987
Drug: Placebo Oxymetazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puffs of each nasal spray in each nostril in the pm
Study: NCT01581138
Drug: VX-222
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablets twice daily for oral administration
Study: NCT01581138
Drug: telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1125 mg tablets twice daily for oral administration
Study: NCT01581138
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
Study: NCT04192903
Drug: Chidamide combined with Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 75mg/m2 ivgtt D1 Chidamide :20mg PO Biw, 2 week on , 1 week off
Study: NCT03988920
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NHE3 Inhibitor
Study: NCT03988920
Drug: Sevelamer Carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphate binder
Study: NCT03259958
Drug: Donepezil TDS
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil Hydrochloride Transdermal Delivery System
Study: NCT03259958
Drug: Aricept
Normalized name: Aricept
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aricept Tablet
Study: NCT00798005
Drug: XRP0038 (NV1FGF)
Normalized name: NV1FGF
DrugBank: Riferminogene pecaplasmid (DB06394)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03598426
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Study: NCT01395758
Drug: ARQ 197 plus erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
Study: NCT01395758
Drug: Pemetrexed, docetaxel or gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
Study: NCT01759771
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 IU of VD3 for at least one year
Study: NCT02528188
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
Study: NCT04470401
Drug: AbobotulinumtoxinA
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
Study: NCT04470401
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: application of 1cc of placebo (saline) or 1cc of abobotulinumtoxinA in both subscapularis and pectoral major muscles
Study: NCT02359370
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
Study: NCT02359370
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
Study: NCT00206375
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone + Synthroid + Lupron
Study: NCT00206375
Drug: Growth hormone treatment and puberty
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron once a month and growth hormone daily
Study: NCT00064012
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00064012
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01174290
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~1. Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~2. The patient is discharged from the ICU at Tufts MC.~3. 10 days of study drug administration occurs.~4. The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy.
Study: NCT00453375
Drug: BHT-3021
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Study: NCT00453375
Drug: BHT-Placebo
Normalized name: BHT
DrugBank: Butylated hydroxytoluene (DB16863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Study: NCT02181660
Drug: Gilteritinib
Normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral